BTK and B-cell chronic lymphocytic leukemia: Treatment with a BTK inhibitor before SARS-CoV-2 vaccination, as well as qualitative differences for immune stimulation between vaccination and infection, may also have contributed to the blunted vaccination responses observed in patients with CLL or WM on BTK inhibitors.